Synthesis, cytotoxicity, and DNA interactions of new cisplatin analogues containing substituted benzimidazole ligands

Journal of Medicinal Chemistry

Volumn 52, Issue 5, 2009, Pages 1345-1357

  Gümüş, Fatma ^a   Eren, Gökçen ^a   Açik, Leyla ^a   Çelebi, Ayten ^b   Öztürk, Fatma ^a   Yilmaz, Şükran ^c   Saǧkan, Rahşan Ilikçi ^d   Gür, Sibel ^e,f   Özkul, Aykut ^e   Elmali, Ayhan ^e   Elerman, Yalçin ^e  

^a GAZI UNIVERSITY   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

^c Foot and Mouth Disease Institute   (Turkey)

^d GULHANE SCHOOL OF MEDICINE   (Turkey)

^e ANKARA UNIVERSITY   (Turkey)

^f AFYON KOCATEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN DERIVATIVE; NUCLEOPHILE; PLASMID DNA;

ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL POPULATION; CELL STRAIN MCF 7; CHEMICAL MODEL; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DRUG ACTIVITY; DRUG DNA INTERACTION; DRUG EFFECT; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; FLOW CYTOMETRY; GEL ELECTROPHORESIS; HELA CELL; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDROPHOBICITY; LIGANDS; MOLECULAR STRUCTURE; NUCLEIC ACID CONFORMATION; PLASMIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 64349094401     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8000983     Document Type: Article

References (56)

1. Chaney, S. G.; Sancar, A. DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response. J. Natl. Cancer Inst. 1996, 88, 1346-1360.
2. Xin Zhang, C.; Lippard, S. J. New Metal Complexes as Potential Therapeutics. Curr. Ovin. Chem. Biol. 2003, 7, 481-489.
3. Jamieson, E. R.; Lippard, S. J. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem. Rev. 1999, 99, 2467-2498.
4. Wang, D.; Lippard, S. J. Cellular Processing of Platinum Anticancer Drugs. Nat. Rev. Drug Discovery 2005, 4, 307-320.
5. Brabec, V.; Kasparkova, J. Molecular Aspects of Resistance to Antitumor Platinum Drugs. DrugResist. Updates 2002, 5, 147-161.
6. Ohndorf, M. A.; He, R. Q.; Pabo, C. O.; Lippard, S. J. Basis for Recognition of Cisplatin-Modified DNA by High-Mobility-Group Proteins. Nature 1999, 399, 708-712.
7. He, Q.; Liang, C. H.; Lippard, S. J. Steroid Hormones Induce HMG1 Overexpression and Sensitize Breast Cancer Cells to Cisplatin and Carboplatin. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 5768-5772.
8. Zamble, D. B.; Mikata, Y.; Eng, C. H.; Sandman, K. E.; Lippard, S. J. Testis-Specific HMG-Domain Protein Alters the Responses of Cells to Cisplatin. J. Inorg. Biochem. 2002, 91, 451-462.
9. Brown, S. J.; Kellet, P. J.; Lippard, S. J. Ix1, a Yeast Protein That Binds to Platinated DNA and Confers Sensitivity to Cisplatin. Science 1993, 261, 603-605.
10. Tallen, G.; Mock, C.; Gangopadhyay, S. B.; Kangarloo, B.; Krebs, B.; Wolff, J. E. A. Overcoming Cisplatin Resistance: Design of Novel Hydrophobic Platinum Compounds. Anticancer Res. 2000, 20, 445-450.
11. Reedijk, J. New Clues for Platinum Antitumor Chemistry: Kinetically Controlled Metal Binding to DNA. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 3611-3616.
12. Reardon, J. T.; Vaisman, A.; Chaney, S.; Sancar, A. Efficient Nucleotide Exicion Repair of Cisplatin, Oxaliplatin, and Bis-acetoammine- dichlorohexylamine-platinum(IV) (JM216) Platinum Intrastrand DNA Diadducts. Cancer Res. 1999, 59, 3968-3971.
13. Reedijk, J. Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell? Chem. Rev. 1999, 99, 2499-2510.
14. Kostova, I. Platinum Complexes as Anticancer Agents. Recent Pat. Anti-Cancer Drug Discovery 2006, 1, 1-22.
15. Gümüş, F.; Aİzgü, F.; Algül, Ö. Synthesis and Structural Characterization of Some 5(6)-Substituted-2- Hydroxymethylbenzimidazole Derivatives and Their Platinum(II) Complexes and Determination of Their in Vitro Antitumor Activities by "Rec-Assay Test". FABAD Farm. Bil. Der. 1996, 21, 7-15.
16. Gümüş, F.; Pamuk, İ.; Özden, T.; Yildiz, S.; Diril, N.; Öksüzoǧlu, E.; Gür, S.; Özkul, A. Synthesis, Characterization and in Vitro Cytotoxic, Mutagenic and Antimicrobial Activity of Platinum(II) Complexes with the Substituted Benzimidazole Ligands. J. Inorg. Biochem. 2003, 94 (3), 255-262.
17. Gümüs., F.; Algül, Ö.; Eren, G.; Eroǧlu, H.; Diril, N.; Gür, S.; Özkul, A. Synthesis, Cytotoxic Activity on MCF-7 Cell Line and Mutagenic Activity of Platinum(II) Complexes with 2-Substituted Benzimidazole Ligands. Eur. J. Med. Chem. 2003, 38, 473-480.
18. 2] Complexes. Pharmazie 2003, 58 (5), 303-307.
19. 2] Complexes. Eur. J. Med. Chem. 2005, 40, 135-141.
20. Algül, Ö.; Özçelik, B.; Abbasoǧlu, U.; Gümüş, F. Synthesis, Characterization and Genotoxicity of Platinum(II) Complexes with Substituted Benzimidazole Ligands. Turk. J. Chem. 2005, 29, 607-615.
21. Gümüs, F.; Algül, Ö. DNA Binding Studies with cis-Dichlorobis5(6)non/chlorosubstituted-2-hydroxymethylbenzimidazole Platinum(iI) Complexes. J. Inorg. Biochem. 1997, 68 (1), 71-74.
22. Knobloch, W. Synthese von Substituierten Benzimidazolen mit Potentieller Antitumorwirkung. Chem. Ber. 1958, 91, 2557-2561.
23. Jones, J. B.; Taylor, K. E. Hydroxymethylbenzimidazole Carboxylic Acid Models of the Asp-His-Ser Charge Relay System of Serine Proteases. Can. J. Chem. 1977, 55 (10), 1653-1657.
24. Bachman, G. B.; Heisey, L. V. Monomers and Polimers: The Preperation of Vinyl Derivatives of Five-Atom Heterocyclic Rings. J. Am. Chem. Soc. 1949, 71, 1985-1988.
25. Bednyagina, N. P.; Postovskii, I. Ya. Hydrolytic Cleavage of Some Sulfones of Heterocyclic Series. Sythesis and Properties of pNitrophenylsulfonyl-N-methylbenzimidazolylmethane and p- Nitrophenylsulfonylbenzothiazolylmethane. Zh. Obshch. Khim. 1960, 30, 3193-3196 (Chem Abstr. 1961, 55, 19908i).
26. Porai-Koshits, B. A.; Kvitko, I. YA.; Shutkova, E. A. Synthesis of Aminoesters of Benzimidazole Derivatives. Zh. Prikl. Khim. 1964, 37 (6), 1386-1388.
27. Tertov, B. A.; Koblik, A. V.; Avdyunina, N. I. Organosodium Compounds of N-Substituted Benzimidazoles. Chem. Heterocycl. Compd. 1971, 7 (9), 1163-1167.
28. Tunali, N. K.; Özkar, S. Anorganik Tepkime Mekanizmalari. In Anorganik Kimya, 4th ed.; Gazi Publishing: Ankara, Turkey, 1999; pp 373-402.
29. 1H-NMR Spectra and Conformational Implications. Inorg. Chim. Acta 1981, 55, 125-128.
30. 1?H-NMR and IR Spectroscopic Data of 1,3-Diphenylpropane-1,3-diamines and Their Pt(II) Complexes: Stereochemical Assigments and Binding Mode of the Non-Amine Ligands. Arch. Pharm. 1994, 327, 697-707.
31. Lippert, B. Platinum Nucleobase Chemistry. Prog. Inorg. Chem. 1989, 37, 1-97.
32. Cini, R.; Fanizzi, F. P.; Intini, F. P.; Maresca, L.; Natile, G. Platinum Amides from Platinum Nitriles: X-ray Crystal Structures of the Unbridged Dinuclear Compounds Bis[bis(1-imino-1-hydroxy-2,2dimethylpropane)(1-amino-1-oxo- 2,2-dimethylpropane)dichloroplatinum(II)]. J. Am. Chem. Soc. 1993, 113, 5123-5131.
33. Schreiber, A.; Hillgeris, E. C.; Lippert, B. On Metal Modified Nucleobase Pairs and Triples. Z. Naturforsch. 1993, 48b, 1603-1612.
34. Wheate, N. J.; Collins, J. G. Multi-Nuclear Platinum Drugs: A New Paradigm in Chemotherapy. Curr. Med. Chem.: Anti-Cancer Agents 2005, 5, 267-279.
35. II Complexes Retain Their N-Donor Ligands. J. Med. Chem. 2007, 50, 4075-4086.
36. Gust, R.; Schnurr, B.; Krauser, R.; Bernhardt, G.; Koch, M.; Schmid, B.; Hummel, E.; Schonenberger, H. Stability and Cellular Studies of [rac-1,2-Bis(4-fluorophenyl)-ethylenediamine][cyclobutane-1,1-dicarboxylato] platinum(II), a Novel, Highly Active Carboplatin Derivative. J. Cancer Res. Clin. Oncol. 1998, 124, 585-597.
37. Gust, R.; Krauser, R.; Schmid, B.; Schonenberger, H. Breast Cancer Inhibiting Diastereomeric Diacetato[1,2-bis(4-fluorophenyl)ethylenediamine] platinum(II) Derivatives: Synthesis and Studies on the Relationship between Reactivity and Antitumor Activity. Inorg. Chim. Acta 1996, 250, 203-218.
38. Gust, R.; Krauser, R.; Schmid, B.; Schonenberger, H. Synthesis and Antitumor Activity of [1,2-Bis(4-fluorophenyl)ethylenediamine][dicarboxylato] platinum(II) Complexes. Arch. Pharm. (Weinheim, Ger.) 1998, 331, 27-35.
39. Gust, R.; Heinrich, H.; Krauser, R.; Schonenberger, H. [meso- and rac-1,2-Bis(4-fluorophenyl)ethylenediamine]chloro[sulfinyl-bis(methane)S] platinum(II) Chloride New Water Soluble Platinum Complexes with High Anti-Breast Cancer Activities. Inorg. Chim. Acta 1999, 285, 184-189.
40. Bernhardt, G.; Koch, M.; Spruss, T.; Gust, R.; Krauser, R.; Schlemmer, R.; Hollstein, M.; Lux, F.; Schonenberger, H. [meso-1,2-Bis(2,6dichloro-4- hydroxyphenyl)ethylenediamine]sulfato-platinum(II). Phar- macokinetic Studies. Arch. Pharm. (Weinheim, Ger.) 1999, 332, 195-200.
41. Gust, R.; Keilitz, R.; Krauser, R.; Schmidt, K.; Schnurr, B. Structure Activity Studies on Leaving Group Derivatives of [meso-1,2-Bis(2,6- dichloro-4-hydroxyphenyl)ethylenediamine]-platinum(II). Arch. Pharm. (Weinheim, Ger.) 1999, 332, 261-270.
42. Schertl, S.; Hartmann, R. W.; Batzl-Hartmann, C.; Bernhardt, G.; Spruss, T.; Beckenlehner, K.; Koch, M.; Krauser, R.; Schlemmer, R.; Gust, R.; Schonenberger, H. [1,2-Bis(2,6-difluoro-3-hydroxyphenyl) ethylenediamine] platinum(II) Complexes, Compounds for the Endocrine Therapy of Breast Cancer. Mode of Action II: Contribution of Drug Inactivation, Cellular Drug Uptake and Sterical Factors in the Drug Target Interaction to the Antitumor Activity. Arch. Pharm. (Weinheim, Ger.) 2004, 337, 349-359.
43. Cohen, G. L.; Bauer, W. R.; Barton, J. K.; Lippard, S. J. Binding of cis- and trans-Dichlorodiammineplatinum(II) to DNA Evidence for Unwinding and Shortening of the Double Helix. Science 1979, 203, 1014-1016.
44. Keck, M. V.; Lippard, S. J. Unwinding of Supercoiled DNA by Platinum-Ethidium and Related Complexes. J. Am. Chem. Soc. 1992, 114, 3386-3390.
45. Neplechova, K.; Kasparkova, J.; Vrana, O.; Novakova, O.; Habtemar- iam, A.; Watchman, B.; Sadler, P. J.; Brabec, V. DNA Interactions of New Antitumor Aminophosphine Platinum(II) Complexes. Mol. Pharmacol. 1999, 56, 20-30.
46. Fuertes, M. A.; Alonso, C.; Pérez, J. M. Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance. ChetThRev. 2003, 103, 645-662.
47. Khazanov, E.; Barenholz, Y.; Gibson, D.; Najajreh, Y. Novel Apoptosis-Including trans-Platinum Piperidine Derivatives: Synthesis and Biological Characterization. J. Med. Chem. 2002, 45 (24), 5196-5204.
48. Roberts, R. S.; Wilson, G. A.; Young, F. E. Recognition Sequence of Specific Endonuclease BamHI.1 Form Bacillus amyloliquefa- ciens. Nature 1977, 265, 82-84.
49. Gonzales, V. M.; Fuertes, M. A.; Alonso, C.; Perez, J. M. Is Cisplatin- Induced Cell Death Always Produced by Apoptosis? Mol. Pharmacol. 2001, 59, 657-663.
50. Mueller, S.; Schittenhelm, M.; Honecker, F.; Malenke, E.; Lauber, K.; Wesselborg, S.; Hartmann, J. T.; Bokemeyer, C.; Mayer, F. Cell-Cycle Progression and Responce of Germ Cell Tumors to Cisplatin in Vitro. Int. J. Oncol. 2006, 29, 471-479.
51. Ishibashi, T.; Lippard, S. J. Telomere Loss in Cells Treated with Cisplatin. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4219-4223.
52. Tardito, S.; Bussolati, O.; Gaccioli, F.; Gatti, R.; Guizzardi, S.; Uggeri, J.; Marchio, L.; Lanfranchi, M.; Franchi-Gazzola, R. Non-Apoptotic Programmed Cell Death Induced by a Copper(II) Complex in Human Fibrosarcoma Cells. Histochem. Biol. 2006, 126, 473-482.
53. Perez, R. P. Cellular and Molecular Determinants of Cisplatin Resistance. Eur. J. Cancer 1998, 34 (10), 1535-1542.
54. Raymond, E.; Faivre, S.; Chaney, S.; Woynarowski, J.; Cvitkovic, E. Cellular and Molecular Pharmacology of Oxaliplatin. Mol. Cancer Ther. 2002, 1, 227-235.
55. Spingler, B.; Whittington, D. A.; Lippard, S. J. 2.4 Å Crystal Structure of an Oxaliplatin 1,2-d(GpG) Intrastrand Cross-Link in a DNA Dodecamer Duplex. Inorg. Chem. 2001, 40, 5596-5602.
56. Souchard, J. P.; Ha, T. T. B.; Cros, S.; Johnson, N. P. Hydrophobicity Parameters for Platinum Complexes. J. Med. Chem. 1991, 34, 863-864. JM8000983